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Hepatitis B virus (HBV) is one of the causative agents of hepatocellular carcinoma. The molecular mechanisms of
tumorigenesis are complex. One of the host factors involved is apparently the long-lasting inﬂammatory reaction which
accompanies chronic HBV infection. Although HBV lacks a typical viral oncogene, the HBx gene encoding a pleiotropic
regulatory protein emerged as a major player in liver carcinogenesis. Here we review the tumorigenic functions
of HBx with an emphasis on wild type and truncated HBx variants, and their role in the transcriptional dysregulation
and epigenetic reprogramming of the host cell genome. We suggest that HBx acquired by the HBV genome
during evolution acts like a cellular proto-onc gene that is activated by deletion during hepatocarcinogenesis. The
resulting viral oncogene (v-onc gene) codes for a truncated HBx protein that facilitates tumor progression. Copyright
© 2015 John Wiley & Sons, Ltd.
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Alongside alcohol consumption, exposure to aﬂa-
toxin B1, hemochromatosis and hepatitis C virus
(HCV) infection, human hepatitis B virus (HBV)
infection is the main cause of hepatocellular carci-
noma (HCC) worldwide. Chronic HBV infection
accounts for more than half of HCC cases, and
more than 80% of HCCs in highly endemic coun-
tries like China. HBV, a small DNA virus from ther: Hans H. Niller, Institute for Medical Microbi-
University of Regensburg, Franz-Josef-Strauss
gensburg, Germany.
.Niller@klinik.uni-regensburg.de
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5 John Wiley & Sons, Ltd.Orthohepadnavirus genus of the Hepadnaviridae
family, has a partially double-stranded, relaxed-
circular genome (RC-DNA). After infecting
non-dividing hepatocytes, HBV RC-DNA is
converted into covalently closed circular DNA
(cccDNA) with the contribution of the cellular
DNA repair machinery, followed by transcription
and replication of the genome. HBV replication
does not necessarily involve integration of HBV
DNA into the cellular genome [1,2] (reviewed by
[3,4]).
HBV causes acute, mostly resolving or, at a
smaller percentage, persistent liver disease. Ap-
proximately 2 billion people are infected, whereas
350 million are estimated to be chronic carriers of
HBV which means that their infected hepatocytes
express hepatitis B surface antigen (HBsAg) and
shed HBsAg and viral DNA into their blood
stream. Chronic HBV infection frequently results
H. H. Niller et al.in liver cirrhosis which facilitates the development
of HCC in a multistep process. Compared to
non-infected individuals, the risk of HCC develop-
ment in chronic HBV carriers and patients with
chronic liver disease is about 30 times and 100
times higher, respectively. Mass vaccinations in
high incidence areas successfully curbed HCC inci-
dence [5]. Therefore, HBV is clearly causative
for hepatocarcinogenesis. However, HBV does not
code for a generally acknowledged oncoprotein,
although the product of the viral HBx gene may
play such a role. Thus, the molecular mechanisms
of HBV-associated hepatocarcinogenesis are still a
major riddle of tumor virology (reviewed by [6,7]).
Gene expression patterns, genetic and epigenetic
modiﬁcations distinguish HBV-associated HCC
from HCC of other origins. Integration of the
HBV genome into the host cell DNA, modulation
of apoptotic and cell signaling pathways by the
pleiotropic, full length HBx protein (wild type
HBx, wtHBx) and its C-terminal truncated
variants (trHBx proteins) or other viral proteins,
epigenetic dysregulation, transcriptional repro-
gramming, chronic inﬂammation, generation of
reactive oxygen species and immune reactions all
contribute to HBV-associated carcinogenesis
(reviewed by [6–10]). Here we wish to focus on the
contribution of wtHBx comprising 154 amino acid
residues and its C-terminal truncated variants
(trHBx) to HCC development. trHBx proteins were
regularly observed in HCCs and differ signiﬁcantly
from wtHBx in their biological activities (reviewed
by [10]). A similar phenomenon was observed dur-
ing the generation of certain oncoproteins encoded
by retroviral oncogenes, too. It is well documented,
that the 5′ or 3′ sequences of cellular proto-onc
genes transduced by retroviruses as v-onc genes
are frequently deleted [11]. Such deletions may
profoundly affect the properties of the encoded pro-
teins, as exempliﬁed by the C-terminal truncated
variant of the cellular c-myb (myeloblastosis)
protein in mice [12]. Similarly, a truncated Cbl
(Casitas B-lineage lymphoma) protein also acts as
the viral oncoprotein of a murine retrovirus [13].
The C-terminal truncation that generated the v-cbl
oncogene altered the intracellular localization,
DNA binding properties and transforming poten-
tial of the Cbl protein [14]. Thus, one possibility
certainly is that wtHBx may be activated by
3′-deletion to a viral oncogene coding for trHBx
which contributes to oncogenesis.Copyright © 2015 John Wiley & Sons, Ltd.HBV GENOME: TRANSCRIPTIONAL
REGULATION
Both covalently closed, circular HBV genomes
persisting as episomes in the host cell nucleus and
HBV genomes integrated into the host cell DNA
are transcribed by the cellular RNA polymerase II
(Pol II). From the episomal genomes, Pol II gener-
ates both viral mRNAs translated in the cytoplasm
and viral pregenomic RNA molecules (pgRNAs)
that act as the template for the synthesis of minus-
strand viral DNA by the viral reverse transcriptase,
followed by plus strand DNA synthesis inside the
capsid [15]. In addition to cellular transcription
factors (TFs) and the epigenetic regulatory machin-
ery of the host cell, the viral wtHBx protein is also
involved in the regulation of HBV gene expression.
Host factors regulating HBV transcription:
the metabolovirus model
A multitude of cellular TFs are involved in the
regulation of HBV gene transcription. Most of them
are involved in the regulation of major hepatocellu-
lar metabolic pathways, e. g. gluconeogenesis,
bile-acid production and fat accumulation. This
has led Shaul and colleagues to propose the term
“metabolovirus” for HBV and suggest that viral
gene expression may be regulated by nutritional
cues [16,17]. The response to nutritional signals
may be mediated by peroxisome proliferator-
activated receptor-gamma coactivator 1alpha
(PGC-1α) which is a central coactivator of glucose
metabolism [18]. PGC-1α synergizes with the
forkhead factor FoxO1 and the nuclear receptor
HNF-4α in the induction of key metabolic genes
in hepatocytes. Similarly, both, FoxO1 and HNF-
4α bind to both viral enhancers and the core
promoter and coactivate viral gene transcription
together with PGC-1α [19]. The strong dependency
of viral gene transcription on liver speciﬁc TFs
may constitute the most important post-receptor
restriction element for the liver tropism of HBV.
Besides PGC-1α, the viral wtHBx protein is the
other important coactivator of HBV gene transcrip-
tion. By binding together with CREB and C/EBP to
HBV enhancers, wtHBx upregulates HBV tran-
scription [20–22].
Epigenetic regulation of the HBV genome
HBV gene expression is typically controlled by two
enhancers, four promoters and three CpG islandsRev. Med. Virol.
DOI: 10.1002/rmv
Hepatitis B virus: HBx-induced patho-epigenetics(Figure 1). CpG island 1 (CGI 1) is associated with
the HBs gene start codon, CGI 2 is associated with
both enhancers and the core (HBc)- and X gene
(HBx)-promoters, and CGI 3 is associated with the
polymerase gene start codon [22–24]. However,
the numbers and distribution of CGIs in HBV
genomes differ to some extent depending on the
viral genotype [25].
Clearly, HBV gene expression is regulated by epi-
genetic mechanisms, including DNA methylation
and histone modiﬁcations. The encapsidated viral
DNA was unmethylated, just like viral DNA in
the liver of patients with chronic active hepatitis,
whereas in occult HBV infection as well as in HCC
and hepatoma cell lines, a variable methylation
pattern of HBV DNA was observed [24,26–32].
Methylation of the HBs and HBc genes correlated
with a lack of expression, whereas the HBx gene
was frequently unmethylated even in genomeswhich
were highlymethylated at other loci [31]. Methylation
of transfected viral genomes strongly decreased HBs
and HBc gene transcription from viral cccDNA inFigure 1. The HBV genome: enhancers, CpG islands and open
reading frames. The circular HBV genome is represented by a dark
grey line. E1, E2: position of enhancers. CGI1, CGI2 and CGI3: po-
sition of CpG islands. Arrows indicate open reading frames. ORF
X: HBx; PC: precore protein; core: core protein; ORF P: polymerase
protein; Pre S1: domain of the large surface protein; Pre S2: domain
of the large and middle surface proteins; S: major surface protein
Copyright © 2015 John Wiley & Sons, Ltd.cultured hepatoma cells and silenced integrated viral
genomes in HBV-transgenic mice [33].
The viral genome is not only subject to CpG-
methylation, but it also actively inducesDNAmethyl-
transferases (DNMTs).Hepatoma cell lines responded
to HBV infection with an upregulation of DNMTs
resulting in methylation-mediated transcriptional
silencing of the viral genome and suppression of
virus replication [34]. Methylation of HBV DNA is
regarded as an antiviral cellular defense mecha-
nism. However, silencing of cellular tumor suppres-
sor genes by promoter hypermethylation may be an
inadvertent side effect of this defense mechanism
which then may contribute to tumorigenesis [34]
as discussed later (see “Epigenetic dysregulation
in HBV infected cells: The role of wtHBx”).
The nuclear HBV genome is organized into nu-
cleosomes like a minichromosome [35]. In addition
to histones, the viral protein HBc is also part of the
viral chromatin [36]. HBc, a positive regulator of
HBV transcription, preferentially bound to CGI 2,
and facilitated TF binding and hypomethylation
in liver biopsy samples [37]. Transcriptionally
active cccDNA genomes were associated with
acetylated histones H3 and H4 and histone acetyl
transferases (HATs) including p300, CBP and
PCAF/GCN5. Histone deacetylases (HDAC)
HDAC1 and hSirt1 were also recruited to cccDNA.
Indirect binding of HBx to the viral cccDNA
enhanced viral replication and transcription in hep-
atoma cells and human biopsy samples [38–40].
In primary hepatocytes or differentiated hepaRG
cells, HBx relieved histone methyl transferase
SETDB1-mediated transcriptional repression of vi-
ral cccDNA [41]. IFNα-treatment of HBV-carrying
cells or hepatocytes of humanized transgenic mice
silenced HBV transcription and replication directly
via an interferon-stimulated response element
(ISRE) located at the HBx promoter/enhancer 1 re-
gion of the viral genome. IFN-treatment resulted in
histone deacetylation at the cccDNA in hepatoma
cells and in human hepatocytes colonizing trans-
genic mice. In addition to HDAC, the polycomb
group proteins EZH2 and YY1 were also recruited
to the HBx promoter [42].
INTEGRATION OF HBV DNA INTO THE
CELLULAR GENOME
Reverse transcription of pregenomic viral RNA in
cytoplasmic nucleocapsids of hepadnavirus infected
cells is initiated by the HBV reverse transcriptase thatRev. Med. Virol.
DOI: 10.1002/rmv
H. H. Niller et al.also acts as a priming protein. The synthesis yields
predominantly relaxed-circular HBV DNAs [1,43].
There is another pathway for viral DNA synthesis,
however, that generates duplex-linear DNA
(DL-DNA). Deletions of HBV sequences indispens-
able for the formation of RC-DNA may increase the
synthesis of DL-DNA [1]. Both open circular and
linear HBV DNA molecules, generated in replica-
tion complexes recycled to the nucleus, may initiate
integration events that frequently result in dele-
tions or rearrangements both in the viral genome
and the invaded cellular DNA [44]. It was sug-
gested that HBV integration events may potentially
contribute to oncogenesis by altering the activity of
targeted host genes [45]. In a recent massively
parallel sequencing study of HCC samples, HBV
integration was more frequent in the tumors
(86.4%) compared to adjacent liver tissues (30.7%).
Within the HBV genome, most of the breakpoints
were located in a region comprising the viral
enhancer, the HBx gene encoding the regulatory
protein wtHBx and the core gene [46]. Deletion of
the 3′ HBx sequences is a regular consequence of
integration [47] and results in the expression of
C-terminal truncated HBx (trHBx) proteins that dif-
fer in their properties from the full length wtHBx
protein. One may speculate that the cellular repair
enzymes involved in the RC to cccDNA transition
[2,4] may play a role in the generation of HBx dele-
tions. As a matter of fact, a triple helix region in the
relaxed, nicked-circular DNA of the HBV genome
may facilitate integration into the cellular DNA
[48]. Corresponding to this region on the viral
genome, virus–cell junctions of integrated viruses
clustered just upstream of the expected right-hand
end of the DL-DNA at nt 1832. Thus, viral
breakpoints mostly locate to the 3′-end of the HBx
gene [45,49].
HBV integration into the human genome occurs
at the early steps of hepatocarcinogenesis and
seems to be a random event [50]. Still, HBV integra-
tion at fragile sites of the human genome may alter
the expression of close-by oncogenes, tumor sup-
pressor genes and miRNA genes and promote, at
least to some extent, tumorigenesis (reviewed by
[50]). HBV integration brings about multiple
mutagenic events, like deletions, translocations
and gross chromosomal abnormalities. Compared
to non-viral or HCV-related HCC, the rate of
chromosomal aberrations is signiﬁcantly increased
in HBV-induced HCC. Thus, viral insertion mayCopyright © 2015 John Wiley & Sons, Ltd.initiate speciﬁc oncogenetic pathways. HBV-driven
mutational activity combined with the increased
cell turnover in chronic hepatitis constitutes a
constantly operating selection system for better than
average growing cells [51]. Indeed, the expansion
of normal appearing cell clones occurred in tumor-
adjacent normal tissue from HBV-HCC patients.
Those clones were not restricted to cirrhotic nod-
ules, but occurred also in normal liver tissue and
comprised at least 1%, possibly up to 50% of the
entire liver tissue [52]. Presumably, those clones of
up to thousands of hepatocytes exhibit an as yet
unknown selective advantage that drives their
expansion within infected livers [49]. It is impor-
tant to distinguish between an initial, possibly
tumor-promoting viral integration event and later
genomic rearrangements which accompany tumor
progression and may even lead to the loss of the
initially integrated viral genome in a hit-and-run
fashion. In a cirrhotic liver the HBV genome was
lost with the progression of genetic instability from
a group of clonally and spatially related cirrhotic
nodules [53], (reviewed by [54]).
HBX: A VIRAL PROTO-ONCOGENE
EVOLVING IN THE COURSE OF MULTISTEP
HEPATOCARCINOGENESIS CODES FOR A
MULTIFUNCTIONAL REGULATORY
PROTEIN
HBV-associated HCCs regularly contain integrated
HBV genomes expressing transcripts for the pleio-
tropic regulatory protein HBx with a relative
molecular mass of 17kD [10]. Full length HBx, desig-
nated as wtHBx in this review, consists of 154 amino
acid residues organized into several functional
domains [55,56] (Figure 2). The conserved N-terminal
“A” region (amino acids 1–20) displayed a trans-
repressor activity: when coexpressed with wtHBx,
it inhibited wtHBx-mediated transactivation in
cultured hepatoma cells [55,57]. A proline and
serine-rich region (region “B”, amino acids 31–57)
separates the transrepressor domain from a larger,
complex C-terminal region involved in transac-
tivation (residues 58–140) that contains a basic do-
main (BD) and a cellular protein binding domain
(CPBD) [55,56]. The C-terminal region (residues
79–117) of wtHBx promoted an efﬁcient IgG anti-
body response both in chronic hepatitis patients
and in symptomless carriers [58]. The C-terminal
region was indispensable for wtHBx stability and
contributed to the wtHBx-mediated stimulation ofRev. Med. Virol.
DOI: 10.1002/rmv
Figure 2. Secondary structure of HBx, genotype C. The conserved N-terminal “A” region (amino acids 1–20) is separated by a proline and
serine-rich region (region “B”, amino acids 31–57) from a larger, complex C-terminal region involved in transactivation (residues 58–140)
that contains a basic domain (BD) and a cellular protein binding domain (CPBD). The C-terminal region stimulates HBV replication and
overlaps with a split Kunitz-like serine protease inhibitor domain (amino acids 61–69 and 131–142) interacting with proteasome subunits.
The α-helical DDB1-binding motif (amino acids 88–100) interacts with damaged DNA binding protein 1 (DDB1) that serves as a docking
platform for substrate receptor proteins in E3 ubiquitin ligase complexes. The amino acid sequence of HBx, HBV genotype C, was
retrieved from the Hepatitis B Virus Database (https://hbvdb.ibcp.fr/HBVdb/HBVdbIndex) and was analyzed using the PSIPRED server
(http://bioinf.cs.ucl.ac.uk/psipred/) as described in [69,70]
Hepatitis B virus: HBx-induced patho-epigeneticsHBV replication [59]. This region overlaps with a
split Kunitz-like serine protease inhibitor domain
(amino acids 61–69 and 131–142) interacting with
proteasome subunits. A nine-amino-acid sequence
(residues 132–140) from the Kunitz domain in-
duced growth arrest and apoptosis of HepG2
hepatoma cells and down-regulated the expression
of p97, an ATPase involved in the ubiquitin protea-
some protein degradation pathway [60]. A promis-
cuous α-helical motif adopted by amino acids 88–
100 of wtHBx ﬁts into a large pocket of damaged
DNA binding protein 1 (DDB1) that serves as a
docking platform for substrate receptor proteins
in E3 ubiquitin ligase complexes [61]. This interac-
tion may redirect the ubiquitin ligase machinery
to a new, unknown substrate, possibly a cellular
protein involved in the antiviral response of the
host cell [61]. The ubiquitin ligase complex includ-
ing DDB1 is involved in the proteolysis of Cdc10-
dependent transcript 1 (CDT1), a replication licens-
ing protein rapidly degraded in S phase to preventCopyright © 2015 John Wiley & Sons, Ltd.inappropriate origin ﬁring [62–64]. CDT1 is de-
graded after DNA damage, a mechanism guarding
genomic integrity [63]. Thus, interaction of wtHBx
with DDB1 may affect the integrity of the genome
by modulating CDT1 degradation. wtHBx also
interacts with single stranded DNA and a series
of DNA repair proteins, resulting in inefﬁcient re-
pair of damaged cellular DNA [65–68]. By blocking
DNA repair, wtHBx may facilitate the ﬁxation of
mutations and play a role in hepatocarcinogenesis.
In silicomodeling of the tertiary structure of wtHBx
revealed structural similarity with the central domain
ofmismatch uracil DNAglycosylase (MUG) enzymes
involved in base-excision repair [71]. Because the
hypothetical, restored translation product of a vesti-
gial protein X reading frame of duck hepatitis virus
showed a similar 3D structure, van Hemert, et al.
speculated that an ancestral hepadnavirus possibly
captured a MUG-like sequence from a host genome
[71]. It was also reported that wtHBx is structurally
and functionally similar to nucleoside diphosphateRev. Med. Virol.
DOI: 10.1002/rmv
H. H. Niller et al.kinases (NDPKs). wtHBx hydrolyzed ATP, trans-
ferred a phosphate group to NDP molecules, phos-
phorylated AMP to ADP and hydrolyzed GTP
[72,73]. On the other hand, wtHBx was found to be
an intrinsically unstructured protein through several
methods, e.g. NMR spectroscopy, circular dichroism
spectropolarimetry and bioinformatics. The intrinsic
disorder may explain the capability of wtHBx to
promiscuously interact with a multitude of target
proteins [74].
It is important to note that the various HBV
genotypes (A–J) that differ in geographical distri-
bution are different as to their pathogenicity as well
[75–77]. Infection with HBV genotypes C and D
were linked to a more severe course of liver disease
[76]. In addition, genotype C, the most prevalent
genotype in Asia, was highly associated with HCC
[78]. A recent comprehensive analysis found se-
quence differences at distinct positions of the HBx
gene coding for wtHBx in various HBV genotypes
[77]. It is remarkable that in HBV genotype C there
were nucleotide differences (mutations) at seven posi-
tions between HCC and non-HCC patients. Some of
these mutations were present in other HBV geno-
types, too [77]. We note, however, that in HuH-7 cells
the HBV genotype did not inﬂuence the apoptosis-
inducing capacity of wtHBx [79].TRANSCRIPTIONAL ACTIVATION OF HOST
GENES BY WTHBX
By interacting with key TFs, wtHBx inﬂuences
host gene transcription in a pleiotropic manner fa-
cilitating liver carcinogenesis. wtHBx-dependent
transcriptional activation of the cylooxygenase 2
(COX2) promoter, as veriﬁed in HepG2 hepatoma
cells, led to elevated prostaglandin E2 (PGE2) levels
in chronic HBV patients, thus contributing to liver
ﬁbrosis [80]. Transcription of several oncogenes
and SREBP-1a, encoding sterol regulatory element
binding protein-1a, a key regulator for fatty acid
and cholesterol synthesis, was also induced by
wtHBx in cultured hepatoma cell lines [81–83]. In
Huh-7 hepatoma cells, wtHBx activated FoxM1
encoding forkhead box protein M1, a master regu-
lator of tumor metastasis via the ERK/CREB sig-
naling pathway [84]. wtHBx, via NF-κB induction,
also upregulated a cytokine in HBV carriers and
metastasis-associated protein 1 (MTA1), a master
chromatin modiﬁer, in HCCs [85,86]. Another im-
portant TF which responded to wtHBx expressionCopyright © 2015 John Wiley & Sons, Ltd.in cultured AML12 murine hepatocytes is E2F1, a
major regulator of cell cycle-dependent genes [87].
A ChIP-chip approach utilizing anti-HBx anti-
bodies combined with transcriptional proﬁling on
HepG2 hepatoma cells identiﬁed 184 gene targets
directly regulated by wtHBx, via the interaction
with 144 TFs. Among the six signaling pathways
affected by wtHBx, the Jak-STAT pathway was
the most prominent [88].
wtHBX AND trHBX TRANSGENIC MOUSE
MODELS
The pleiotropic actions of wtHBx are also reﬂected
in transgenic mouse models. Transgenic mice
carrying the wtHBx gene under the control of the
HBVenhancer 1 developed progressive histopatho-
logical changes, starting with multifocal areas of
altered hepatocytes, later developing benign ade-
nomas and ending in malignant HCCs. Male mice
developed HCCmuch earlier, reﬂecting the skewed
male-pronounced gender ratio of HCC in humans
[89]. Another mouse line with a similar transgenic
DNA construct yielded tumors after prolonged
latency, or biliary duct cysts that possibly corres-
ponded to degenerated tumor tissue [90,91]. Koike,
et al. observed that low-level wtHBx-expression
did not lead to HCC in HBx-transgenic mice,
whereas high-level long-term wtHBx-expression
led to HCC, preferentially in males [92]. Other
wtHBx-transgenic mouse lines did not yield HCC
at all [93,94]. A mouse line expressing wtHBx
under the control of a liver-speciﬁc cellular pro-
moter showed only minor histologic alterations.
However, the liver carcinogen diethylnitrosoamine
(DEN) and wtHBx acted synergistically in the in-
duction of HCC in those mice [95–98]. Carcinogenic
synergism was also observed when DEN was
replaced by aﬂatoxin B1 [99]. Cross-breeding of
c-Myc transgenic mice with wtHBx-transgenic mice
also accelerated tumorigenesis [100,101].
Terradillos, et al. found that transgenic expres-
sion of wtHBx enhanced apoptotic death in the
mouse liver. They speculated that subsequent cy-
cles of cell killing and liver regeneration may select
the outgrowth of cell populations resistant to the
proapoptotic activity of wtHBx, partly mediated
by stimulating the c-myc promoter [102]. Such
hepatocyte populations may progress, thereafter,
to HCC. In other transgenic models wtHBx
inhibited the regeneration of liver tissue in a para-
crine manner or led to a premature cell cycle entryRev. Med. Virol.
DOI: 10.1002/rmv
Hepatitis B virus: HBx-induced patho-epigenetics[103–106]. In addition, wtHBx increased the resis-
tance of hepatocytes to reactive oxygen species via
upregulation of forkhead protein FoxO4 [107].
Quetier, et al. generated transgenic mice expressing
either wtHBx or trHBx [108]. They could not ob-
serve HCC development in either group. Treatment
of young transgenic mice with the liver carcinogen
DEN resulted, however, in the development of liver
carcinomas. There was a more rapid onset of HCC
in the animals expressing trHBx than in the wtHBx
transgenic mice [108]. Overall, the transgene experi-
ments showed that the efﬁciency of integrated
HBx in causing HCC in mice is variable and depends
on multiple factors. For this reason the HBx gene
encoding wtHBx is not generally acknowledged
as a classical viral oncogene, although it can induce
hepatocarcinogenesis in certain HBx-transgenic
strains or may act as a tumor promoter and cofactor.
ABROGATION OF THE ANTI-PROLIFERATIVE
AND APOPTOTIC EFFECTS OF wtHBX IN
trHBX VARIANTS DEFECTIVE IN
TRANSACTIVATION
wtHBx has been reported to either block [109–112]
or induce [112–117] apoptosis. These apparently
discrepant results may be explained through
concentration-dependent effects during different
stages of infection [9,118]. Alternatively, HBx
mutations may alter the apoptosis-related proper-
ties of HBx proteins as well. Expression of wtHBx
inhibited colony formation of cells in vitro and
induced apoptosis by a p53-independent pathway
in a set of different cell lines. In contrast, HBx-
mutants derived fromHCCs including a mutant se-
quence with both point mutations and a C-terminal
truncation resulting in the loss of 26 C-terminal
amino acid residues did not interfere with cell
growth and lost their transactivation properties,
suggesting that the transactivating functions of
HBx may be irrelevant to oncogenesis [56].
Further, C-terminal truncations of HBx may
explain why HBx was found to induce both apo-
ptosis and anti-apoptosis. In rat embryo ﬁbroblasts,
wtHBx acted as a growth-suppressive and pro-
apoptotic protein that blocked the transforming
activity of cellular proto-oncogenes or viral onco-
proteins [119]. Similarly, Tu, et al. observed that in
contrast to wtHBx, most of the trHBx proteins
obtained from HCCs failed to block cell prolifera-
tion and oncogene-mediated transformation of
primary rat embryo ﬁbroblasts in vitro [119].Copyright © 2015 John Wiley & Sons, Ltd.The proapoptotic function of wtHBx was mapped
to the C-terminal transactivation domain [120].
We note, however, that the situation is complex,
because depending on the cell type studied and
on the actual experimental conditions, wtHBx was
either capable to induce apoptosis or to elicit an
anti-apoptotic response in a context-dependent
manner (reviewed by [121]).
wtHBx and trHBx differ as to their intracellular
localization. In transfected cells, wtHBx accumulated
in the cytoplasm and associated with the mitochon-
dria [122–124]. In human liver biopsies derived from
patients with chronic HBV infection the localization
was also predominantly cytoplasmic, although
exclusively nuclear or cytoplasmic and nuclear
localization was also observed [125]. trHBx ex-
pressing transfected HepG2 cells displayed, how-
ever, a predominant nuclear localization [124].
Because wtHBx facilitates the translocation of Bax,
a proapoptotic protein, to mitochondria and causes
fragmentation and swelling of the organelle
[122,126,127], one may speculate that the lack of
proapoptotic function of trHBx is partly because
of its altered cellular localization.
Integration of HBV DNA into the cellular
genome is not required for viral replication. Still,
HBV tends towards multiple integrations during
chronic infection. IntegratedHBV sequenceswere ob-
served in 80–90% of HCC cases [46,128], (reviewed
by [50,129]). Viral integrants isolated from HCCs
contained trHBx genes coding for C-terminal trHBx
proteins unable to transactivate and unable to sup-
press cell proliferation [119]. Instead of suppressing
the transforming functions of oncogenes, like
wtHBx proteins did, the trHBx proteins enhanced
the transforming abilities of those oncogenes [119].
Sequencing of 14 viral integration sites in HCCs
revealed rearrangements of the viral genome in all
cases; in 10 of 14 cases HBx was truncated at the
C-terminus [130]. Using immunochemistry with
antibodies detecting either full length HBx only or
both full length and trHBx proteins, Ma, et al.
detected trHBx in 88 out of 111 HCC tissue samples
(79%), whereas wtHBx was present in 23 of 111
tumorous tissues (20.7%) [47]. In cultured hepato-
cytes, expression of trHBx, but not wtHBx
transformed the immortalized cell line MIHA [47].
Sze, et al. found trHBx mRNA and protein, respec-
tively, in 23 and 22 out of 50 HCCs; wtHBx only
occurred in the tumor-surrounding liver tissue,
where trHBx was absent. Expression of trHBXRev. Med. Virol.
DOI: 10.1002/rmv
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10 (MMP10) expression and angiogenesis [131].
Furthermore, a comprehensive analysis of a set of
more than one thousand integrated HBV sequences
from diverse genotypes and disease stages showed
that HCC-associated mutations clustered within the
C-terminal end of the HBx gene, especially for geno-
type C. Some of these mutations preexisted already
at pretumoral disease stages [77].
Analysis of microRNA transcription in cells
expressing wtHBx or trHBx showed that hepatocytes
expressing trHBx grew faster and showed a de-
creased expression of a set of growth-suppressive
microRNAs, while wtHBx increased the expression
of that miRNA set [132]. Thus, C-terminal truncation
of wtHBx seems to be important for the development
of HCC (Table 1). The deletion may be causal at the
beginning of liver tumorigenesis by providing anti-
apoptotic functions for naturally apoptosis-bound
oncogenic cells, or the growth-suppressive functions
of the HBx C-terminus may be selected against at a
later stage of tumor development.
wtHBXMAY DRIVE SEQUENTIAL EVENTS OF
HEPATOCARCINOGENESIS FROM A
CHRONICALLY HBV INFECTED
PREMALIGNANT STATE TO METASTATIC
HEPATOCELLULAR CARCINOMA
wtHBx induced supernumerary centrosomes and
multipolar spindles in cultured cells, and aneuploidy
of chromosomes 1 and 6 was detected in HBV
infected hepatocytes of chronically HBV infected pa-
tients prior to the development of HCC. These events
were attributed to the wtHBx-mediated induction ofTable 1. Biological effects and properties of wtH
Effect/property
Stimulation of HBV replication
Induction of apoptosis
Inhibition of cell growth
Transactivation
Inhibition of cell transformation
Predominant localization
Expression in hepatocellular carcinoma cells
Expression in nontumorous tissues
Enhancement of invasiveness and metastasis formation
Copyright © 2015 John Wiley & Sons, Ltd.cytoplasmic sequestration of Crm1, a nuclear export
receptor preventing extra centriole synthesis [138].
Thus, wtHBx may initiate hepatocarcinogenesis by
eliciting genomic instability and chromosomal aber-
rations already at a pretumoral stage.
Chronic HBV infection may result in necrosis and
rapid regeneration of hepatocytes, accompanied
with ﬁbrosis that leads eventually to cirrhosis, the
most important precancerous condition predisposing
to HCC development [133,139] (Table 1). wtHBx
induced transforming growth factor-β (TGF-β) secre-
tion in hepatocytes that activated, in a paracrine
manner, the proliferation and gene expression of
hepatic stellate cells (HSCs) [139]. Because HSCs are
the main producers of extracellular matrix proteins
in the ﬁbrotic liver, HBx appears to be an important
player in the development of liver cirrhosis.
wtHBx may also utilize a paracrine mechanism
to inhibit the proliferation of hepatocytes. This
process may select, however, for cells resistant to
paracrine inhibition [103]. Thus, wtHBx mutations
or truncations abrogating the proapoptotic effect of
the protein [119], or changes to the differentiation
status of hepatocytes may result in hyperplastic hepa-
tocyte nodules that may progress to dysplastic
nodules, the putative precursors of HCC [133]. In
the livers of HBx-transgenic mice dysplastic lesions
displayed a more intensive staining for wtHBx,
hypoxia-inducible factor-1 alpha (HIF1α) and vas-
cular endothelial growth factor (VEGF) compared
to non-neoplastic regions [140]. Abnormally large
blood vessels were also detected in the dysplastic
lesions where capillary-like microvessels were
more abundant than in non-neoplastic regions.Bx and trHBx
Protein
wtHBx trHBx Reference
Yes No [59]
Yes No [120]
Yes No [56,119]
Yes No (?) [56]
Yes No [119,120]
Cytoplasm Nucleus [122–124,127]
Yes Yes [47]
Yes No [131]
Yes Yes [131,133–137]
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increased the transcriptional activity of HIF1α, a
subunit of the TF HIF-1 that controls angiogenesis
and VEGF expression, Moon, et al. suggested that
wtHBx may promote hepatocarcinogenesis by the
induction of angiogenesis already in the dysplastic
nodules, i.e. at an early stage of neoplastic develop-
ment [140].
wtHBx induced the disruption of adherens junc-
tions resulting in the dissociation of the cadherin–
cytoskeleton interaction and decreased homotypic
adhesion between hepatocytes [141]. Because the loss
of cadherin-dependent adhesion facilitates cell migra-
tion and invasive behavior, Lara-Pezzi, et al. specu-
lated that by disrupting cell–cell adhesion wtHBx
may induce the progression from adenoma to carci-
noma [141]. wtHBxmay also facilitate invasion by in-
creasing cell motility and matrix metalloproteinase-9
(MMP-9) production [133–137]. Upregulation of
MMP-1 and cyclooxygenase-2 (COX-2) expression
by wtHBx also correlated with enhanced tumor cell
invasion [142]. wtHBx expression facilitated the
generation of intrahepatic and lung metastases in
nude mouse, possibly by inducing epithelial–Table 2. The role of wtHBx and trHBx in succes
Stage HBx structure
Premalignant hepatic lesions wtHBx
Cirrhosis wtHBx
Hyperplastic nodule wtHBx, mutated HBx,
Dysplastic nodule wtHBx, mutated HBx,
Adenoma wtHBx, mutated HBx,
Carcinoma wtHBx, mutated HBx,
Invasion wtHBx, mutated HBx,
Metastasis wtHBx, mutated HBx,
Copyright © 2015 John Wiley & Sons, Ltd.mesenchymal transition (EMT), a phenomenon
associated with changes of cell morphology and
behavior [143–145]. As mentioned above, trHBx
enhanced the invasive ability of transfected cells
by activating MMP10 expression [131] (Table 2).
We notice here that there are also other scenarios
of hepatocarcinogenesis. Although worldwide more
than 90% of HCC are based on previous cirrhosis,
about 40% of HCC in the southern half of Africa
arise without previous cirrhotic lesions (reviewed by
[146]). In these patients, chromosomal instability
(CIN) appears to be an important factor in HCC
development (reviewed by [147,148]).
EPIGENETIC DYSREGULATION IN HBV
INFECTED CELLS: THE ROLE OF wtHBX
Epigenetic modiﬁcations especially DNA methyla-
tion patterns clearly distinguish HBV-associated
HCC from HCC of other origins. Alcohol-caused
HCC correlated with hypomethylation at O-6-
methylguanine-DNMT (MGMT), while glutathione
S-transferase P (GSTP1) was hypermethylated in
HBV-associated HCC [149]. Methylation at the
kallikrein-10 (KLK10) promoter correlated withsive stages of hepatocarcinogenesis
Effect
Centrosome abnormalities
Paracrine stimulation, proliferation
of hepatic stellate cells, collagen
deposition
Induction of cyclooxygenase-2,
increased PGE2 production, ﬁbrosis
Induction of hepatocyte apoptosis
Paracrine stimulation, inhibition of
liver cell proliferation
Selection of liver cells carrying deleted
HBx genes
Selection of apoptosis-resistant,
proliferating liver cells
trHBx (?)
trHBx Induction of angiogenesis
trHBx Loss of homotypic adhesion
trHBx Epithelial–mesenchymal transition
trHBx Increased motility, production of
metalloproteinases
trHBx Increased motility, production of
metalloproteinases
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H. H. Niller et al.HCV-associated cirrhosis and HCC, but correlated
inversely with HBV [150]. Recent methylome
analyses supported these early observations and
revealed the presence of both etiology-speciﬁc and
shared DNA methylation alterations in HCCs
[149,151].
The mechanisms involved in the alteration of
host cell methylation patterns in HBV infected cells
remain to be clariﬁed. Vivekanandan, et al. sug-
gested that HBV infection may induce DNMTs that
methylate and silence the viral genome and act
as effectors of an antiviral defense mechanism [34]
(see also “Epigenetic regulation of the HBV
genome”). Hypermethylation of distinct cellular
promoters may be a byproduct of such a defense
mechanism. Another possibility is that one or
several HBV proteins expressed in the host cells
interact with the cellular epigenetic machinery
and cause epigenetic dysregulation. The best candi-
date for such a role is wtHBx. The role of trHBx in
the alteration of the host cell epigenome remains
to be established. We note however, that the epige-
netic alterations induced by wtHBx in hepatocytes
during the initial phase of carcinogenesis may
persist at a later stage, after the appearance of trHBx
as well (epigenetic memory). The role of trHBx in
epigenetic dysregulation remains to be established.
In HBV-associated HCCs distinct epigenetic
changes occurred already at early stages of carcino-
genesis. The tumor suppressor genes APC, RASSF1A
and SOCS1 were methylated in a fraction of HBV-
associated cirrhotic nodules. The methylation levels
of APC and RASSF1 increased further in low-grade
dysplastic nodules, whereas SOCS1-methylation
peaked in early HCC, and decreased in advanced
liver carcinomas [152].
Methylation proﬁles based on the analysis
at 27 000 CpG-dinucleotides within 14 495 pro-
moters of single hepatocytes from HBV-associated
HCC tumor tissue distinguished malignant, tumor-
adjacent and normal hepatocytes [153]. A set of
seven genes were hypermethylated in malignant,
but hypomethylated in tumor-adjacent hepato-
cytes, whereas a distinct group of nine genes was
hypermethylated both in malignant and non-
malignant tumor-adjacent hepatocytes. The latter
data supported the epigenetic ﬁeld theory for
cancerization [154], and other observations of an
epigenetic ﬁeld during HCC development [155].
Hypermethylation at the CGIs of p16INK4A and
CCND2 was increased with progredient tissueCopyright © 2015 John Wiley & Sons, Ltd.damage from normal tissue via cirrhosis to HCC,
indicating that hypermethylation of the p16 locus
may prepare the ground for hepatocarcinogenesis
[156]. The promoter of sFRP1, a gene coding for
secreted frizzled-related protein 1 that blocks Wnt
signaling, was signiﬁcantly more often silenced by
hypermethylation in HCC than in surrounding tis-
sue and may be an early marker of HCC [157].
E-cadherin is a key cellular adhesion protein which
acts as a tumor suppressor. Its absence leads to a
more invasive growth and metastasizing behavior
of tumor cells. In preneoplastic tissue and early
stages of HCC, the E-cadherin (CDH1) promoter
was silenced by DNA methylation [158–161].
wtHBx induced transcriptional repression of CDH1
via activation of DNMT1 and increased cell migra-
tion [162,163]. In addition to increased promoter
methylation, build-up of a complex of repressor pro-
teins also contributed to the silencing of E-cadherin
transcription. wtHBx recruited the corepressor pro-
tein mSin3A, which is the core of an HDAC complex,
to the CDH1 promoter [164].
Premature senescence which acts as a tumor sup-
pressing mechanism through growth arrest in G1
was blocked in HepG2 cells by wtHBx-mediated
hypermethylation at p16 [165]. DNMT1 induction
possibly occurred via the p16INK4A-cyclin D1-
CDK4/6-pRb-E2F1 pathway [166–168]. In addition
to the upregulation of DNMT1 expression, wtHBx
also induced two splice variants of the de novo
DNMT DNMT3A (DNMT3A1 and DNMT3A2) in
hepatoma cell lines resulting in hypermethylation
of the tumor suppressor gene IGFBP3 via recruit-
ment of DNMTs and MeCP2 to the IGFBP3
promoter [169]. wtHBx silenced additional cellular
promoters as well by recruiting DNMT3A2 or
upregulating DNMT1 and DNMT3A [170–173]. In
contrast, wtHBx downregulated DNMT3B, the
other de novo DNMT. Because DNMT3B is in-
volved in the methylation of satellite 2 repeats,
those sequences where hypomethylated [169]. It is
worthy to note that LINE1 repetitive sequences
were found to be hypomethylated in the sera from
HCC patients and hypomethylation correlated
with HBs carrier status, large tumor sizes and poor
survival [174]. The same methylation patterns,
methylation at IGFBP3 and global hypomethyla-
tion at repetitive sequences were found in HCC
biopsies from 20 patients. Thus, HBV infection
may accelerate hepatocarcinogenesis by epigenetic
means right after the beginning of HBV infectionRev. Med. Virol.
DOI: 10.1002/rmv
Hepatitis B virus: HBx-induced patho-epigenetics[169]. In addition to promoter hypermethylation,
other mechanisms are also involved in wtHBx-
induced repression of cellular genes, including
wtHBx/HDAC1 complex formation and deacety-
lation of the TF Sp1 [170,175]. Gene activation by
wtHBx was also observed, via removal of DNMT3A
from cellular promoters or induction of promoter
hypomethylation [170,176].
Lee, et al. compared the methylomes of hepato-
cytes from normal and wtHBx-transgenic mice
using the methylated CpG island recovery assay
(MIRA) [177]. They observed a decrease in global
DNA methylation both in 3-month-old and
13-month-old wtHBx-transgenic mice with HCC.
In addition to the demethylation of the satellite
elements, intragenic CpG islands overlapping the
distal exons were also frequently hypomethylated
in HBx-induced liver tumors [177]. It is worthy to
note, that in contrast to promoter-associated
CpG islands where hypomethylation typically
correlates with promoter activity, a reduction of tran-
script levels was observed at the hypomethylated
intragenic CpG islands. Lee, et al. argued that
wtHBx-mediated downregulation of the murine
Dnmt3a and its partner, Dnmt3l, resulted in hypo-
methylation of intragenic CpG islands. wtHBx
bound to the major Dnmt3l promoter in wtHBx-
transgenic mouse hepatocytes and possibly silenced
it via the recruitment of HDAC1 [177]. Further
studies may clarify the inconsistencies between the
in vitro and in vivo data regarding the effect of
wtHBx on human DNMT3A and murine Dnmt3a
levels, respectively [169,177]. It also remains to
be established how the methylation patterns of
intragenic CpG islands change in HBV infected
human cells.Copyright © 2015 John Wiley & Sons, Ltd.CONCLUSION
Based on the fundamental differences between the
effects of wtHBx and trHBx on cell physiology
and the regular appearance of trHBx during HCC
development we suggest that HBx acts similarly
to a proto-onc gene acquired during evolution by
the HBV genome. Only the full-length HBx gene,
coding for a proapoptotic, “wild type” HBx protein
(wtHBx) is transmitted during the viral replication
cycle.
Expression of wtHBx in infected hepatocytes
induces genetic and epigenetic alterations and
may elicit necrosis and rapid compensatory prolif-
eration of hepatocytes, accompanied with ﬁbrosis
that leads eventually to cirrhosis, the most impor-
tant precancerous condition predisposing to HCC
development. In parallel, in distinct hepatocytes
of newly infected individuals HBx is activated by
deletion, in analogy to some retroviral v-onc genes
resulting in a viral oncogene, that codes for an
antiapoptotic, C-terminal trHBx protein that
stimulates cell proliferation and facilitates develop-
ment and progression of HCC. In the hepatocytes
of HCC patients, coexpression of wtHBx and trHBx
was demonstrated in distinct hepatocyte popula-
tions. HCC typically develops, however, from
proliferating hepatocytes carrying deleted HBV
genomes coding for trHBx.
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